Abstract: This invention relates to monoclonal antibodies to interferon alpha and to hybridomas producing such antibodies. These antibodies are preferably of the immunoglobulin subclass IgGl and preferably do not bind to alpha or alpha interferon. They can be used in assaying, purifying or isolating proteins, such as interferon alpha, for which they are specific.

Abstract: An aqueous, flavored, topical, nasal decongestant composition containing an amount of oxymetazoline or a pharmaceutically acceptable salt thereof, e.g., oxymetazoline HCl sufficient to effect nasal decongestion and an amount of a fruity flavor e.g. cherry flavor, sufficient to mask the medicinal after-taste of the composition, together with an aqueous carrier.

Abstract: A shaped container of a size suitable having an insert having a face coated with a dry water-soluble dyeing composition and a method of dyeing eggs using said shaped containers and a kit containing various shaped containers, each having therein different dry water-soluble dyeing compositions.

Abstract: A non-cariogenic confectionery base free of cellulosics and graining compounds containing hydrogenated starch hydrolysates e.g. Lycasin 85%, more than 10 to about 50% by weight of at least one edible oil, fat, wax or mixtures thereof and an emulsifying amount of at least one emulsifier and a method of making same are disclosed. A non-cariogenic confectionery composition containing said confectionery base in homogeneous admixture with a semi-solid matrix containing various ingredients and optionally at least one medicament is also disclosed.

Abstract: A multistep process is disclosed for preparing azetidinone intermediates used in the making penems and carbapenems wherein intermediates containing ##STR1## R' is independently hydrogen or 1, 2 or 3 of lower alkyl or lower alkoxy, preferably hydrogen, wherein R" is methyl, ethyl, a phenyl or alkyl, preferably ethyl, as a readily removable nitrogen protecting group are made.

Abstract: 3-O-Glycosyl derivatives of 16-membered macrolides such as O-.alpha.-L-cladinosyl-(1.fwdarw.3)-12,13-dehydro-12,13-deoxorosaramicin, 2", 4",4'"-tri-O-acetyl-O-(4'-O-phenoxyacetyl-.alpha.-L-cladinosyl)-(1.fwdarw. 3)-desmyconsin and pharmaceutically acceptable acid addition salts thereof useful as antibacterials are disclosed.

Abstract: Condylomata Acuminata infections (anogenital warts) are treated in infected patients by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks.The interferon exemplified is recombinant DNA human interferon alfa-2b in which 1.0.times.10.sup.6 International Units are administered by injection to each lesion.The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means.

Abstract: A method is provided for extracting human interleukin-4 (IL-4) from IL-4 expressing bacterial cells. The method comprises treating the bacterial cells with a deactivating agent, disrupting the cell membrane and recovering the IL-4.

Abstract: The novel triacetylenic dioxolone antifungal compound of this invention is isolated from the EV-22 complex of this invention which is elaborated by the microorganism Microbispora sp. SCC 1438, ATCC 53620.

Abstract: There is disclosed an improved process for preparing albuterol which comprises reacting a 5-(haloacetyl)-2-hydroxybenzaldehyde with 1,1-dimethylethanamine in an organic solvent and in an inert atmosphere to form 5-[[(1,1-dimethylethyl)amino]acetyl]-2-hydroxybenzaldehyde and reducing the carbonyl functions to the corresponding hydroxy groups to form albuterol.

Abstract: There is disclosed a novel microorganism Aspergillus niveus, ATCC 20922, and a process for chiral reduction of ketones using said microorganisms.

Abstract: There is disclosed a compound represented by the formula ##STR1## wherein each P is hydrogen or a hydroxy protecting group and R and R' are each the same and are hydrogen, ##STR2## wherein R" is lower alkyl and R'" is a carboxy protecting group. The compounds are useful as intermediates for preparing penems.

Abstract: A method and composition for suppressing the immune response are disclosed which employ an immunosuppressing effective amount of certain substituted spiro pyridine derivatives.

Abstract: Non-aqueous sunscreen oils having a high SPF value and containing a volatile oil such as a volatile silicone oil, an emollient containing esters of straight and branched chain C.sub.10 -C.sub.16 alcohols and C.sub.4 -C.sub.20 mono- or dicarboxylic acids such as tridecyl stearate and an ester of a straight or branched-chain C.sub.10 -C.sub.16 alcohol and a tri(loweralkyl) substituted benzoic acid such as tridecyl trimellitate, esters of branched-chain C.sub.5 -C.sub.10 glycols and C.sub.4 -C.sub.20 mono- and dicarboxylic acid such as the diester of neopentyl glycol and decanoic acid and the diester of neopentyl glycol and octanoic acid and a sunscreening effective amount of at least two UV-B type sunscreens and at least one UV-A type sunscreen.

Abstract: 1-Substituted naphthyridines and pyrido-pyrazines are disclosed which are useful in treating allergic reactions, inflammation, peptic ulcers and hyperproliferative skin diseases and in suppressing the immune response in mammals. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed.

Abstract: The use of an angiotensin converting enzyme inhibitor for reducing and controlling the elevation of intraocular pressure associated with the use of corticosteroids is disclosed. Also disclosed are the use of the combination of an angiotensin converting enzyme inhibitor and a steroid, and pharmaceutical compositions comprising the combination.

Abstract: The present invention relates to ophthalmological pharmaceutical compositions comprising a renin inhibitor and to methods for using said composition in the treatment of glaucoma.

Abstract: Methods and pharmaceutical compositions are disclosed for reducing intraocular pressure. The methods and compositions employ an active ingredient which comprises certain benzothiadiazinyl and quinazolinyl substituted carboxyalkyl dipeptides wherein the benzothiadiazinyl or quinazolinyl portions are joined to the dipeptide portions by an aminocarbonyl group.